A Single-Center, Open-Label, Randomized, Single-Dose, Four-Period, Two-Sequence, Fully Replicate Crossover Trial to Assess the Bioequivalence of Test Product Sacubitril and Valsartan Tablets (Strength: Sacubitril 97 mg/ Valsartan 103 mg) and Reference Product (ENTRESTO®) (Strength: Sacubitril 97 mg/ Valsartan 103 mg) in Healthy Adult Participants under Fed Conditions (ChiCTR) - Oct 16, 2026 - P=N/A | N=44 | Not yet recruiting | Sponsor: Hangzhou Combak Hospital; Zhejiang Arthur Pharmaceutical Co., Ltd.
New trial • Cardiovascular • Heart Failure
|